SLS, IBRX And IOVA Join Merck And Lilly On BlackRock’s Q3 Buy List — A Vanguard Unit Adds All Of Them Too
BlackRock and a Vanguard unit added SLS, IBRX, IOVA, MRK, and LLY to their Q3 buy lists. Lilly reported strong sales from diabetes, obesity, and cancer drugs. Sellas (SLS) awaits Phase 3 trial results for its AML treatment. ImmunityBio (IBRX) plans expanded FDA approval for Anktiva. Iovance (IOVA) saw 77% YoY sales growth for Amtagvi and is testing it with Merck's (MRK) Keytruda. Retail sentiment varies across stocks.
How this was made

The 30-second read
Why it matters
Each firm has a distinct regulatory or partnership catalyst that could drive short‑term price moves.
Market read
Fresh FDA‑related news and high‑profile partnerships provide actionable trading ideas in the oncology biotech space.
What to watch
Potential competition from other AML and bladder cancer therapies could limit upside.
Background
The article aggregates recent developments for several cancer‑focused biotech firms that appeared on BlackRock and Vanguard buy lists.
Ticker impact
Sellas Therapeutics disclosed timing of its Phase 3 Regal trial and potential FDA approval for its AML immunotherapy GPS, a fresh catalyst for the stock.
likely upward pressure as investors price in potential approval
Phase 3 trial reaching final analysis is a material event for a biotech, often driving share gains.
ImmunityBio reported improved response rates when adding its bladder cancer drug Anktiva to BCG and plans to seek expanded FDA approval by year‑end.
likely upward pressure as market anticipates regulatory clearance
Positive early data and a clear regulatory path are strong upside drivers for a small‑cap biotech.
Iovance highlighted its Amtagvi sales surge and a Phase 3 trial combining Amtagvi with Merck's Keytruda for advanced melanoma, adding a high‑profile partnership.
likely upward pressure as investors value the Merck collaboration
Collaboration with a major pharma and robust sales growth are positive signals for the company's outlook.
Market effects
Positive FDA progress may lift broader oncology biotech sector.
US biotech market sees fresh catalyst, supporting sector momentum.
Regulatory approvals in oncology have worldwide relevance for cancer therapy pipelines.
Counterpoint
If trial data later disappoints, stocks could face sharp reversals.
Key entities
- companySellas Therapeutics
Biotech developing AML immunotherapy GPS.
- companyImmunityBio
Biotech advancing bladder cancer therapy Anktiva.
- companyIovance Biotherapeutics
Cell‑therapy developer partnering with Merck on melanoma.


